RT @CJTsaiMDPhD: 1)🚨Just out @TheLancet - CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer. http…

RT @drdavidpalma: We made it! Today we completed accrual for the SABR-COMET-10 trial! As far as I know, it's the first phase III oligomet…

RT @DrSymYoung: @drviviantan presenting 5-year clinical outcomes for patients with solitary vs bilateral kidneys treated with SBRT at #ASTR…

RT @drdavidpalma: Here is our DART RCT, led by @Melissa_O_Neil! Using a diagnostic CT for planning of urgent palliative treatments substan…

RT @DrSymYoung: Exciting RCT presented at #ASTRO2023 by @Melissa_O_Neil on use of diagnostic CT in lieu of CT sim for palliative patients,…

RT @drviviantan: Published “Top 10 Lessons Learned from Trials in Oligometastatic Cancers” in CRT reviewing #SABR outcomes, toxicity, costs…

RT @tyldesley_scott: An Updated Analysis of the Survival Endpoints of ASCENDE-RT - out in Red Journal

RT @drdavidpalma: Here is the protocol for our DART RCT of palliative RT without CT simulation ⬇️⬇️⬇️ Led by our star radiation therapis…

RT @Melissa_O_Neil: Hot off the digital presses...the DART RCT protocol is now published in BMC Palliative Care We…

RT @DrOlsonOncology: Should Stereotactic Ablative Radiotherapy Be Used for Oligometastatic Disease? | NEJM Evidence

RT @drdavidpalma: In the new @IJROBP Oligomets Special Issue (part 2), we look at SABR planning trade-offs in 2 papers: one from SABR-COMET…

RT @JCO_ASCO: 🔥 Check out what’s hot this week in #JCO: Oligometastases: Emerging Evidence ➡️ #radonc @drdavidpalm…

@changjeesuk1 Thanks Jee Suk! Agree that these can be important barriers.

Many phase III trials are ongoing and will help to define the oligometastatic state, identify biomarkers, and confirm the benefits observed in phase II studies.

RT @changjeesuk1: Final version of manuscript is now available online @IJROBP Again, the OMD state could represent a continuous spectrum o…

RT @DrOlsonOncology: Proud of my team in BC for completing the SABR-5 trial, which demonstrates SABR is safe in patients treated for oligom…